Johnson & Johnson's IMAAVY Gets FDA Priority Review in Rare Anemia

Johnson & Johnson (NYSE:JNJ) reported positive Phase 2/3 ENERGY trial results for IMAAVY (nipocalimab) in warm autoimmune hemolytic anemia (wAIHA), a rare anemia with no currently FDA-approved therapies. The drug significantly improved hemoglobin levels and fatigue in trial patients, with a safety profile consistent with prior use. These data supported a supplemental Biologics License Application (sBLA), which has received U.S. FDA Priority Review.

The Product

IMAAVY (nipocalimab) is a monoclonal antibody targeting the FcRn receptor, reducing circulating autoantibodies. In the ENERGY trial, it met its primary endpoint with significant hemoglobin improvement versus placebo, along with fatigue reduction. IMAAVY is also being studied across multiple autoimmune indications.

Pricing and Availability

Johnson & Johnson has not yet disclosed pricing or a commercial launch timeline for IMAAVY. Pricing will likely be determined upon FDA approval, expected during the Priority Review period.

Competition

There are currently no FDA-approved therapies for wAIHA, positioning IMAAVY as a potential first-in-class treatment. Current off-label treatments include steroids and non-specific immunosuppressants with significant side effects. Competitors in development include rozanolixizumab.

Potential Impact on the Company

IMAAVY represents a significant opportunity for Johnson & Johnson to strengthen its rare disease and autoimmune portfolio. If approved, it could generate substantial sales given the lack of approved alternatives. Success in wAIHA may also support its use in other indications, driving future growth.